Glioblastoma Vaccine to Be Tested as Orphan Drug, Easing Clinical Trials Process
August 19th 2017The designation recognizes that the vaccine, an immunotherapy called SurVaxM, would treat a rare disease, defined as one that affects a patient population of less than 200,000 Americans. However, because it acts on a protein that appears in 80 percent of cancers generally, SurVaxM may have wider applications.